1. Introduction {#s0005}
===============

The CHDs are present in 75--80% of patients with a Homo sapiens autosomal 22q11 (HSA22q11) deletion.[@b0005] Defects in heart separation, including atrial septal defect (ASD), atrioventricular canal septal defects (AVSD), conotruncal septal defects, and ventricular septal defect (VSD), represent a major cause of congenital heart disease.[@b0010]

The different deletions of the region 22q11.2 are classified as variations of the same clinical spectrum called the 22q11.2 deletion syndrome. The frequency of the 22q11.2 deletion is of approximately 1:3800 livebirths, and presented as sporadic in about 90% of the cases and inherited in 10%.[@b0015]

Patients with 22q11.2 deletion syndrome are reported by either hemizygous deletion of the 3-Mb or 1·5-Mb interval, including 24--30 genes on chromosome 22q11.2. However, the few patients who have different deletions or rearrangements in the region have not been informative in localising disease genes because these arrangements are non-overlapping.[@b0020] Further, rare studies have been described patients with unique nested microdeletion within the large 3-Mb typically deleted region (TDR).[@b0025]

Conotruncal heart defects origin is the highest incidence among del22q11 patients, mainly interrupted aortic arch type B, truncus arteriosus, tetralogy of Fallot (TOF), and pulmonary atresia.[@b0030] There are few studies that spanned 22q11.2 region using consecutive polymorphic short tandem repeats to detect a smaller deletion in non-syndromic CHD patients.

The aims of this study were to determine the frequency of 22q11.21 deletion in non-syndromic CHD patients with emphasis on ASD, VSD and TOF using STR markers, and identify a minimal critical deleted region in these patients.

2. Patients and methods {#s0010}
=======================

This research was approved by the Medical Ethical Committee of Benha University according to the "World Medical Association Declaration of Helsinki". A written informed consent was obtained.**Patients;** We selected 20 families referred to Cardiology Department, Benha University Hospitals in the period starting from December 2015 to December 2016. Their mean age was 9.6 years, they were 7 males (35%) and 13 females (65%). In addition to 20 healthy control of matched age and gender.

Among them, 2 patients with TOF, 8 patients with ASD, 16 patients with VSD. 15% showed dysmorphic features and 1 cases had MR (5%).

2.1. Inclusion criteria {#s0015}
-----------------------

Congenital heart defects patients with or without extra cardiac anomalies.

2.2. Exclusion criteria {#s0020}
-----------------------

1.Patients with known syndromes such as Down and Holt-Oram syndromes except DiGeorge syndrome combined with CHDs.2.Cardiac cases of non-septal defects as cases of pulmonary stenosis only.3.Other systemic diseases (e.g. Thalassemia and Diabetes).

3. Methods {#s0025}
==========

1.***Clinical evaluation;*** the clinical evaluation was done through taking history of three-generation pedigree construction, pregnancy and delivery histories, exposure to drugs, fever, trauma, irradiation or any maternal chronic illness. Parental ages at birth of the child, family history and developmental milestones were also recorded. Detailed history and examination of cardiac symptoms were done.2.**Polymorphic DNA markers mapping**Three ml. of the peripheral blood samples was collected from the patients using K~2~EDTA as anticoagulant inside vacutainer sterile tubes. Genomic DNA was isolated from peripheral blood leukocytes by QIAamp DNAMini Kit (50 preps), catalog number 51304, Germany (<https://www.qiagen.com/eg/>). The PCR-STR technique was performed using specific primers for microsatellite genotyping that were directly retrieved from Electronic PCR (http:// [www.ncbi.nlm.nih.gov/sutils/e-pcr/](http://www.ncbi.nlm.nih.gov/sutils/e-pcr/){#ir010}; NCBI, USA). Three consecutive polymorphic loci were used and located in the usually 3-Mb deleted region: D22S941, D22S944 and D22S264. The PCR products were tested on 4% agarose gel to investigate the presence of amplification and measure the allelic polymorphisms by Gel Doc™ EZ imager, BIO-RAD.

4. Results {#s0030}
==========

Using triplicate reactions of three polymorphic DNA markers on 22q11.21 region, we found 2 out of 20 families (10%) with 2 offspring affected by ASD combined with PS and TOF respectively with LOH in D22S941 locus [Table 1](#t0005){ref-type="table"}. On the other hand, no LOH was detected in healthy individuals [Table 2](#t0010){ref-type="table"} & [Fig. 1](#f0005){ref-type="fig"}.Table 1Comparison of clinical data according to D22S941 LOH in all studied cases.No LOH\
N = 18LOH\
N = 2*p*N%N%TOF15.6150.195TGA211.100.619Large VSD844.400.495Small VSD844.400.495ASD738.9150.761PS211.1150.284FTT15.600.732Dysmorphic features211.1150.284MR15.600.732Table 2LOH of 22q11.21 STR loci.Families22q11.21 STR lociD22S264D22S941D22S944F1Proband228267195Father228267195Mother228/211267195  F2201Proband228/211267/248201Father228/211267201Mother211290/267/248  F3Proband223290/267/261210/200Father223290/267/261210/200Mother223/207267210  F4Proband223267201Father223281/267/251201Mother223/207284/267201  F5Proband223/202282/263210Father223/216282/263210Mother202282/263202/210  F6Proband202278/261/248200Father223/202278/261/248200Mother216/202278/261/233200  F7Proband214/202292/278/264205Father202292/278/264205Mother214/202278205  F8Proband214289/278/251195/205Father214/202289/278/251205Mother214/202278195/210  F9Proband214/202256/267/242205Father214/202281/256/242205/211Mother214267200/205  F10Proband218256/239/228195Father218228195Mother218256/239/228195  F11Proband233233195Father233233195Mother233256/239/233195  F12Proband214/202284/256201Father214/202284/256201Mother214284201  F13Proband223/202284201Father223/216284201Mother202284201  F14Proband220/202290215Father220/216290/262215Mother202290215  F15Proband220**304** \[LOH\]215Father220304215Mother220291/271215  F16Proband223/200304/268215Father223304/268215Mother200/216304/268215  F17Proband218290205Father218290/262205/211Mother218290200/205  F18Proband; AVSD220/202281/250215Father220/216281/250215Mother202281/263/250215  F19Proband223/215**299** \[LOH\]205Father218/215299205Mother223290/271205  F20Proband228223195Father228223195Mother228223/207195[^1]Fig. 1Microsatellite segregation analysis shows the deletion at marker D22S941 in the affected patient, in contrast, loci D22S944 and D22S264 shows no deletion. F: father; M: mother; P: patient.

Chi-square analysis of the polymorphic percentage of the three used markers showed that polymorphic diversity of the D22S944 is significant less than D22S941 and D22S264 [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Diagrammatic shape for 22q11.21 region shows the used three STS loci, and chi-square analysis of the polymorphic allelic number percentage.

5. Discussion {#s0035}
=============

The data obtained in this study suggest that the 22q11.2 deletion is more frequent in patients with congenital heart defect, in particular septal defects patients. Using triplicate reactions of three polymorphic DNA markers (highly polymorphic markers D22S264, D22S941, D22S944) on 22q11.2 region, our study found 2 out of 20 families (10%) with 2 offspring affected by ASD combined with PS and TOF respectively with LOH in D22S941 locus. On the other hand, no LOH was detected in control group, In case number15 we found that it has just one allele 304 of D22S941 marker from the father and the other allele from the mother is deleted. The same is in case number 19 as the proband has just one allele 299 of D22S941 marker from the father and other allele from the mother is deleted while the remaining18 proband are having alleles both from the mother and the father and showing no deletion**McElhinney et al.,**[@b0005] detected chromosome 22q11 deletion in 12 (10%) of 125 patients (age ranged from15 to 28 years) with a conoventricular (n 100) posterior malalignment (n 14) or conoseptal hypoplasia (n 11) VSD by FISH examination. This is the same percentage as our study.**Beauchesne et al**.,[@b0035] Results of study done by **Beauchesne et al., (2005)** found that 103 Patients underwent testing with FISH analysis. The intracardiac diagnoses consisted of TOF in 77 patients, Pulmonary atresia (PA)/VSD in 23, and Truncus arteriosus (TA) in 3. They identified 6 patients (5.8%) to have 22q11 deletions (3 TOF, 2 PA/VSD, and 1 TA) using Fluorescence in situ hybridization (FISH) for the DiGeorge/ velocardiofacial syndrome chromosome region. Our results reported higher percentage (10%) of CHD patients with HSA22q11 deletions and this due to rare studies that accomplished on non syndromic CHD patients using STR markers on 22q11.2 locus.

The reported incidence of deletion varies between studies and is apparently higher among TOF patients who are syndromic for DGS or VCFS.[@b0040] This is partially agree with our results, where in the current study the higher percentage of the deletion was found in TOF patients with 50% out total TOF patients.

Our results suggest a distinct segment of 22q11.21 as a TOF and ASD susceptibility region around D22S941 marker, therefore, these results indicate the clinical significance of screening 22q11.21 markers for proband for the early diagnoses and design of the treatment strategies.

Few studies have used polymorphic microsatellites that span the HSA22q11 region to detect micro deletion.[@b0045] So the detection of minimal nested micro deletion on 22q11.2 region was rare. Therefore, we recommend usage of STR-based PCR assay in 22q11.2 genotyping, because it provides a higher resolution than traditional FISH analysis. Also, we observed the marked variability between the different studies that may be due to differences in selection of patients, their number, and the method of analysis.

In contrast to our research **Fernandez et al.,** compared the results of three techniques MLPA, FISH and STR in a group of 30 patients affected with 22q11.2 deletion syndrome and found that MLPA correctly called all patients who had been previously diagnosed by FISH and STR Furthermore, this technique resolved seven cases that were undetermined by STR analysis. These results confirm the efficiency of MLPA as a rapid, reliable, economical, high-throughput method for the diagnosis of 22q11.2 deletion syndrome rather than STR.[@b0050]

Using MLPA **Monteiro et al.,** found that the deletion frequency was 33.3 %of 194 cardiac patients.[@b0055] In contrast to our study, Cytogenetic analysis of 78 cardiac patients (age ranged from 1 day to 37 years) revealed a normal G-banded karyotpic pattern with no additional chromosome defects at 550 band stages However, FISH analysis of the same 78 patients showed 68 had a normal FISH pattern while only 10 patient showed del22q11.2 (12.8%).[@b0060]

**Goldmuntz et al.,** in a study designed to determine the frequency of the 22q11 deletion in a large, prospectively ascertained sample of 251 patients (age ranged from 2 to10 years) with conotruncal defects, identified the deletion in 17.9% of the patients. The deletion frequency varied with the primary diagnosis and was highest in patients with interrupted aortic arch and TA (50 and 34.5%, respectively) in contrast to our research where the deletion is presented among patients with PS, TOF and ASD.[@b0040]

**Srichaisawat et al.,** reported that 24 of 83 (28.9%) patients with cardiovascular malformations were found with 22q11.2 deletion syndrome by FISH examination. 19 of 56 (33.9%) patients with conotruncal heart defects and 5 of 27 (18.5%) patients with non-conotruncal heart defects were found to have the deletion. The 22q11 deletion were found in 14 of 24 (58.3%) patients with TOF (95%), 3 in 12 (25%) patients withASD (95%), 1 in 7 (14.3%) patients with PS (95%), 1 in 4 (25%) patients with TGA and 1 in 4 (25%) patients with VSD.[@b0065]

The reported incidence of deletion varies between studies and is apparently higher among TOF patients who are syndromic for DGS or VCFS.[@b0070] This is partially agree with our results, where in the current study the higher percentage of the deletion was found in TOF patients with 50% out total TOF patients.

5.1. Limitations {#s0040}
----------------

Further studies should be done on 22q11.21 in congenital heart disease especially on siblings.
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[^1]: **TOF**: fallot tetralogy, **TGA**: transposition of great arteries, **PS:** pulmonary stenosis**, FTT:** failure to thrive**, MR:** mitral regurge.
